"Even though Aeterna Zentaris out-licensed the rights to perifosine to Keryx Biopharmaceuticals (Nasdaq: KERX ) , I still think it has potential to contribute more to the bottom line than AEZS-130, which Aeterna Zentaris owns entirely. Only about 6,000 adults are diagnosed with AGHD every year."